Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2515-2521

  Giordano, A ^a,b   Gao, H ^a   Cohen, E N ^a   Anfossi, S ^a   Khoury, J ^a   Hess, K ^c   Krishnamurthy, S ^a   Tin, S ^a   Cristofanilli, M ^d   Hortobagyi, G N ^e   Woodward, W A ^f   Lucci, A ^a   Reuben, J M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Departments of Biostatistics   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Departments of Breast Medical Oncology   (United States)

^f Division of Radiation Oncology   (United States)

Author keywords

Bone marrow; Breast cancer; Cancer stem cells; Cd24; Cd44; Circulating tumor cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; HERMES ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CELL ASSAY; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE;

BONE MARROW; BREAST CANCER; CANCER STEM CELLS; CD24; CD44; CIRCULATING TUMOR CELLS;

ALDEHYDE DEHYDROGENASE; ANTIGENS, CD24; ANTIGENS, CD44; BONE MARROW CELLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; SURVIVAL ANALYSIS;

EID: 84884714391     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt223     Document Type: Article

References (33)

1. National Cancer Institute Surveillance Epidemiology andEnd Results (SEER). Cancer survival statistics. Bethesda, MD. http://seer.cancer.gov/statistics. 2007 (31 May 2012, date last accessed).
2. Dontu G, Al-Hajj M, Abdallah WM et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36(Suppl 1): 59-72.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
4. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
5. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 2006; 25: 521-9.
6. Ismail MS, Wynendaele W, Aerts JL et al. Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin Cancer Res 2004; 10: 196-201.
7. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
8. Janni W, Vogl FD, Wiedswang G et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 2011; 17: 2967-76.
9. Bidard FC, Kirova YM, Vincent-Salomon A et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 2009; 20: 1836-41.
10. Schoenfeld A, Kruger KH, Gomm J et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997; 33: 854-61.
11. Muller V, Stahmann N, Riethdorf S et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11: 3678-85.
12. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80-6.
13. Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-21.
14. Reuben JM, Lee BN, Gao H et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur J Cancer 2011; 47: 1527-36.
15. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59.
16. The World Health Organization Histological Typing of Breast Tumors-Second Edition. The World Organization. Am J Clin Pathol 1982; 78: 806-16.
17. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
18. WolffAC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
19. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
20. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-904.
21. Hall C, Krishnamurthy S, Lodhi A et al. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 2012; 118: 342-8.
22. Hall C, Krishnamurthy S, Lodhi A et al. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 2010; 17: 3252-8.
23. Krishnamurthy S, Cristofanilli M, Singh B et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010; 116: 3330-7.
24. Pierga JY, Bonneton C, Vincent-Salomon A et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004; 10: 1392-400.
25. Benoy IH, Elst H, Philips M et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94: 672-80.
26. Wiedswang G, Borgen E, Schirmer C et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006; 118: 2013-9.
27. Kasimir-Bauer S, Hoffmann O, Wallwiener D et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
28. Effenberger KE, Borgen E, Eulenburg CZ et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat 2011; 125: 729-38.
29. Pierga JY, Bidard FC, Mathiot C et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004-10.
30. Bidard FC, Mathiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-33.
31. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-45.
32. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13: 688-95.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.